Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab Neoadjuvant Therapy for Newly Diagnosed High-Grade Brain Glioma
ChiCTR2400087799Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bevacizumab in brain glioma, sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Objective response rate. Started Aug 2024; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
brain glioma
Beyond the preview
Go deeper on ChiCTR2400087799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087799.